(Hikari Fund’s Portfolio)

Darmiyan has developed BrainSee, the first FDA-approved medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI).
BrainSee combines a patient’s brain MRI with cognitive test scores and generates a score between 0 and 100 that helps the doctor determine the likelihood of progression from mild cognitive impairment to Alzheimer’s dementia.